Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Early Phase 1
1(25.0%)
4Total
Phase 1(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06822998Early Phase 1Recruiting

HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors

Role: lead

NCT05861895Phase 1Recruiting

A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors

Role: lead

NCT05386823Phase 1Completed

Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers

Role: lead

NCT05388487Phase 1Unknown

Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors

Role: lead

All 4 trials loaded